PH12014502669B1 - Therapeutic agent or prophylactic agent for dementia - Google Patents
Therapeutic agent or prophylactic agent for dementiaInfo
- Publication number
- PH12014502669B1 PH12014502669B1 PH12014502669A PH12014502669A PH12014502669B1 PH 12014502669 B1 PH12014502669 B1 PH 12014502669B1 PH 12014502669 A PH12014502669 A PH 12014502669A PH 12014502669 A PH12014502669 A PH 12014502669A PH 12014502669 B1 PH12014502669 B1 PH 12014502669B1
- Authority
- PH
- Philippines
- Prior art keywords
- agent
- dementia
- therapeutic agent
- prophylactic
- prophylactic agent
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 230000000069 prophylactic effect Effects 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 206010012289 Dementia Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000013498 tau Proteins Human genes 0.000 abstract 1
- 108010026424 tau Proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012124336 | 2012-05-31 | ||
| PCT/JP2013/065090 WO2013180238A1 (ja) | 2012-05-31 | 2013-05-30 | 認知症治療剤又は予防剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12014502669A1 PH12014502669A1 (en) | 2015-02-02 |
| PH12014502669B1 true PH12014502669B1 (en) | 2020-02-19 |
Family
ID=49673425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014502669A PH12014502669B1 (en) | 2012-05-31 | 2014-11-28 | Therapeutic agent or prophylactic agent for dementia |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20150183854A1 (enExample) |
| EP (2) | EP2857039B1 (enExample) |
| JP (3) | JP5971659B2 (enExample) |
| KR (2) | KR102208283B1 (enExample) |
| CN (1) | CN104602708B (enExample) |
| AR (1) | AR091218A1 (enExample) |
| AU (2) | AU2013268364B2 (enExample) |
| BR (1) | BR112014029566A2 (enExample) |
| CA (1) | CA2875205C (enExample) |
| CY (1) | CY1122530T1 (enExample) |
| DK (1) | DK2857039T3 (enExample) |
| ES (2) | ES2973070T3 (enExample) |
| HR (1) | HRP20192267T1 (enExample) |
| HU (1) | HUE046919T2 (enExample) |
| IL (1) | IL235899B (enExample) |
| LT (1) | LT2857039T (enExample) |
| ME (1) | ME03587B (enExample) |
| MX (1) | MX361128B (enExample) |
| MY (1) | MY172458A (enExample) |
| NZ (1) | NZ630536A (enExample) |
| PH (1) | PH12014502669B1 (enExample) |
| PL (1) | PL2857039T3 (enExample) |
| PT (1) | PT2857039T (enExample) |
| RS (1) | RS59802B1 (enExample) |
| RU (1) | RU2657438C2 (enExample) |
| SG (2) | SG10201805410XA (enExample) |
| SI (1) | SI2857039T1 (enExample) |
| TW (2) | TWI700296B (enExample) |
| WO (1) | WO2013180238A1 (enExample) |
| ZA (1) | ZA201409186B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| EP2709728B1 (en) * | 2011-05-20 | 2019-01-23 | Oligomerix, Inc. | Tau protease methods of use |
| WO2013180238A1 (ja) * | 2012-05-31 | 2013-12-05 | 公立大学法人大阪市立大学 | 認知症治療剤又は予防剤 |
| EP3838921A3 (en) | 2012-07-03 | 2021-09-01 | Washington University | Antibodies to tau |
| TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| US20190224339A1 (en) * | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2018060035A1 (en) * | 2016-09-30 | 2018-04-05 | F. Hoffmann-La Roche Ag | Spr-based dual-binding assay for the functional analysis of multispecific molecules |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| TWI877098B (zh) | 2017-05-30 | 2025-03-21 | 日商帝人製藥股份有限公司 | 抗ｉｇｆ－ｉ受體抗體 |
| MA50629A (fr) | 2017-10-02 | 2021-03-31 | Merck Sharp & Dohme | Composés monobactames de chromane pour le traitement d'infections bactériennes |
| PE20210115A1 (es) | 2017-10-16 | 2021-01-19 | Eisai Randd Man Co Ltd | Anticuerpos anti-tau y uso de los mismos |
| EP3778631A4 (en) | 2018-04-06 | 2022-01-05 | Teijin Pharma Limited | Spns2 neutralizing antibody |
| JP7340794B2 (ja) * | 2018-07-04 | 2023-09-08 | 学校法人 愛知医科大学 | タウのスプライシングを制御するアンチセンスオリゴヌクレオチド及びその用途 |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| JP7429404B2 (ja) * | 2019-08-06 | 2024-02-08 | 慶應義塾 | タウ関連疾患モデルの製造方法 |
| JP7718270B2 (ja) | 2019-09-30 | 2025-08-05 | ニプロ株式会社 | 血液試料を検体とするタウタンパク質検出方法 |
| IL296611A (en) * | 2020-03-19 | 2022-11-01 | Vascular Biosciences | Car peptide for improved coronavirus survival |
| WO2021262791A1 (en) * | 2020-06-25 | 2021-12-30 | Merck Sharp & Dohme Corp. | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN120019071A (zh) | 2022-09-15 | 2025-05-16 | 沃雅戈治疗公司 | Tau结合化合物 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| AU2007261584A1 (en) * | 2006-06-16 | 2007-12-27 | Envivo Pharmaceutical Inc. | Transgenic flies expressing tau and amyloid precursor fragment |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP2440234A4 (en) | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS |
| US20120244174A1 (en) * | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| TR201102696U (tr) * | 2011-05-27 | 2011-06-21 | Turhal Sal�H | Bağlantısız hareketli ürün reklam standı. |
| WO2013180238A1 (ja) * | 2012-05-31 | 2013-12-05 | 公立大学法人大阪市立大学 | 認知症治療剤又は予防剤 |
| JP2018139530A (ja) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
-
2013
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/ja not_active Ceased
- 2013-05-30 ES ES19207405T patent/ES2973070T3/es active Active
- 2013-05-30 SI SI201331636T patent/SI2857039T1/sl unknown
- 2013-05-30 ES ES13797290T patent/ES2763361T3/es active Active
- 2013-05-30 HR HRP20192267TT patent/HRP20192267T1/hr unknown
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/pt not_active Application Discontinuation
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 PL PL13797290T patent/PL2857039T3/pl unknown
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/me unknown
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/hu unknown
- 2013-05-30 AR ARP130101907 patent/AR091218A1/es active IP Right Grant
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/da active
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/zh active Active
- 2013-05-30 RS RS20191640A patent/RS59802B1/sr unknown
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 PT PT137972907T patent/PT2857039T/pt unknown
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
- 2013-05-30 TW TW102119176A patent/TWI700296B/zh active
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/ja active Active
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/lt unknown
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/ko active Active
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/ru active
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/ko active Active
- 2013-05-30 MX MX2014014187A patent/MX361128B/es active IP Right Grant
- 2013-05-30 TW TW109121902A patent/TWI777183B/zh active
-
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
-
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/ja active Active
-
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/ja active Active
-
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/el unknown
-
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502669B1 (en) | Therapeutic agent or prophylactic agent for dementia | |
| PH12017501417A1 (en) | Anti-fap antibodies and methods of use | |
| MY156697A (en) | Modified tuberculosis antigens | |
| SG10201909716RA (en) | Modified j-chain | |
| NZ730763A (en) | Methods of treating a tauopathy | |
| MX393988B (es) | Variantes de interferon a2b. | |
| MX2015006324A (es) | Metodos para la fabricacion de polipeptidos proteoliticamente procesados. | |
| MX371018B (es) | Polipéptidos que tienen actividad de transgalactosilación. | |
| WO2013123432A3 (en) | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases | |
| WO2011113019A3 (en) | Ctla4 proteins and their uses | |
| MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
| MX2013001473A (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
| SG10201805806RA (en) | Modulation of Structured Polypeptide Specificity | |
| MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| SG10201804385YA (en) | Stimulus responsive polymers for the purification of biomolecules | |
| MX2013008702A (es) | Composiciones que contienen anticuerpos glicosilados y sus usos. | |
| WO2012173846A3 (en) | Peptidomimetic macrocycles | |
| IN2014DN05885A (enExample) | ||
| MX368288B (es) | Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple. | |
| IN2015MN00027A (enExample) | ||
| IN2014DN10209A (enExample) | ||
| HK1200724A1 (en) | Chlamydia antigen compositions and uses thereof | |
| WO2013166183A3 (en) | Replikin sequences and their antibodies, therapeutics and vaccines against prion and neurodegenerative disorders | |
| GB201114923D0 (en) | Immunogenic proteins and compositions |